This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.
The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;
18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);
Electrocorticogram (ECOG) score ranges from 0 to 1 points;
Expected survival is greater than 12 weeks；
Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;
There are multiple factors that affect diseases related to intravenous injection and venous blood collection;
The adverse reactions of previous anti-tumor treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score of ≤ 1;
Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;